This inventor holds 6 USPTO granted patents, plus 2 CIPO patents and 5 EPO patents. Top assignees: Metabrain Research, Biophytis, Sorbonne Université. Active years: 2016-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2016-2022
Title: The Innovative Contributions of Sophie N Raynal
Introduction
Sophie N Raynal is a prominent inventor based in Paris, France. She has made significant contributions to the field of medicine, particularly in the treatment of muscle atrophy. With a total of 6 patents to her name, her work focuses on innovative solutions to enhance muscle mass and strength in mammals.
Latest Patents
One of her latest patents involves the use of tryptophan metabolites for treating muscle atrophy. This invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid, and their mixtures or derivatives. The drug is intended to increase and maintain muscle mass and strength, particularly in preventing muscle atrophy and promoting muscle growth in exercising mammals. Another notable patent relates to oxime and alkoxy derivatives for the treatment and prevention of muscle atrophy. This invention aims to limit muscular atrophy and promote muscle growth, especially in aging mammals or those undergoing rehabilitation after muscle loss.
Career Highlights
Sophie has worked with notable companies such as Metabrain Research and Biophytis. Her career reflects a commitment to advancing medical science through innovative research and development.
Collaborations
Throughout her career, Sophie has collaborated with esteemed colleagues, including Franck F Lepifre and Micheline R Kergoat. These partnerships have contributed to her success and the impact of her inventions.
Conclusion
Sophie N Raynal's contributions to the field of medicine through her patents demonstrate her dedication to improving health outcomes related to muscle atrophy. Her innovative work continues to pave the way for advancements in treatment options for mammals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile